Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$289B
16.08
$7.28
0.26
$3.28
2.90%
Price and volume
Market cap
$289B
Beta
0.26
52-week high
$125.14
52-week low
$73.31
Average daily volume
13M
Dividend rate
$3.28
Financial strength
Current ratio
1.536
Quick ratio
0.963
Long term debt to equity
90.485
Total debt to equity
95.959
Dividend payout ratio (TTM)
44.79%
Interest coverage (TTM)
18.06%
Profitability
EBITDA (TTM)
29,105
Gross margin (TTM)
77.08%
Net profit margin (TTM)
28.08%
Operating margin (TTM)
37.69%
Effective tax rate (TTM)
13.31%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
12.04%
Return on equity (TTM)
36.88%
Valuation
Price to earnings (TTM)
16.084
Price to revenue (TTM)
4.515
Price to book
5.62
Price to tangible book (TTM)
66.67
Price to free cash flow (TTM)
23.702
Free cash flow yield (TTM)
4.22%
Free cash flow per share (TTM)
4.94
Dividend yield (TTM)
2.80%
Forward dividend yield
2.90%
Growth
Revenue change (TTM)
1.31%
Earnings per share change (TTM)
8.01%
3-year revenue growth (CAGR)
3.12%
10-year revenue growth (CAGR)
5.11%
3-year earnings per share growth (CAGR)
8.43%
10-year earnings per share growth (CAGR)
16.65%
3-year dividend per share growth (CAGR)
5.49%
10-year dividend per share growth (CAGR)
6.05%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
3 Undervalued Names Too Cheap to Ignore
MarketBeat·4 days ago
AI-Powered Tempus Inks New Multi-Year Merck Deal
Benzinga·1 week ago
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $289B as of March 11, 2026.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 16.08 as of March 11, 2026.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of March 11, 2026, the dividend rate is $3.28 and the yield is 2.9%. Merck & Co. has a payout ratio of 44.79% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for April 07, 2026.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.